Summit Therapeutics is a biotechnology company focused on the discovery and development of novel antibiotic therapies
The company specializes in addressing complex infectious diseases, particularly those caused by antibiotic-resistant bacteria. Summit Therapeutics leverages its proprietary drug development platform to create innovative treatments aimed at improving patient outcomes and combating the growing threat of antibiotic resistance. Through its research and clinical programs, the company seeks to bring forward effective solutions to meet unmet medical needs in the realm of infectious diseases.
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.
Summit Therapeutics Inc. (NASDAQSMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the fourth quarter and year-ended December 31, 2024.
Summit Therapeutics Inc. (NASDAQSMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial results and provide an operational update for the Company on Monday, February 24, 2025, before the market opens.
Summit Therapeutics Inc. (NASDAQSMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. The inducement awards were granted on February 11, 2025. The options have a ten (10) year term and an exercise price of $19.08 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on February 11, 2025. The options were granted from a pool of equity incentives reserved by the Compensation Committee on May 3, 2024 for issuance as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Summit Therapeutics Inc. (NASDAQSMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. The inducement awards were granted on January 10, 2025. The options have a ten (10) year term and an exercise price of $17.85 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on January 10, 2025. The options were granted from a pool of equity incentives reserved by the Compensation Committee on May 3, 2024 for issuance as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.
Summit Therapeutics Inc. (NASDAQSMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will present a corporate overview and an update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab.
